Press releases

STORM Therapeutics announces publication of “RNA-Modifying Enzymes and their Inhibitors” in 2020 Medicinal Chemistry Reviews

Publication provides timely and critical reviews of important topics in medicinal chemistry

30 December 2020, Cambridge, UK: STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, today announced that it was invited to contribute a comprehensive review on the role of RNA-Modifying Enzymes and their inhibitors, which was published today in 2020 Medicinal Chemistry Reviews, Volume 55. This is the annual edition of the journal covering breakthrough target classes and areas of drug discovery.

The review, “RNA-Modifying Enzymes and their inhibitors”, written by Wesley Blackaby, Byron Andrews, Beth Thomas, David Hardick, and Eric A. Miska from STORM Therapeutics provides an account of significant developments in the field of RNA modifications and progress on translating work into small molecule therapies. See link to paper:

The chapter describes the different families of RNA-modifying enzymes and their inhibitors, the links between specific RNA modifications and disease, novel techniques used to detect and quantify RNA modifications, and general features of RNA-Modifying enzymes, including selectivity and druggability.

Keith Bundy, CEO of STORM Therapeutics, said: “We are honored that STORM Therapeutics was invited to contribute this authoritative review of the emerging and highly promising field of drug discovery for RNA epigenetic targets. This reflects our position in the industry as the leading company currently tackling disease through modulating RNA modifying enzymes.”

2020 Medicinal Chemistry Reviews is published by MEDI, the Medicinal Chemistry Division of the American Chemical Society. The Division of Medicinal Chemistry and its members have been driving forces behind the discovery of revolutionary new medicinal agents and thus have had a major impact on human health.


STORM Therapeutics Ltd
Keith Blundy
T: +44 (0)1223 804174

Optimum Strategic Communications
Mary Clark, Eva Haas, Shabnam Bashir
Tel: +44 (0)203 950 9144



STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Storm is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.

STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences and IP Group, who share the team’s ambitions to build a world-leading company in the field.